ABIVAX SA (ABVX)
5.50
-0.36 (-6.14%)
At close: Apr 10, 2025, 11:21 AM
-6.14% (1D)
| Bid | 5.27 |
| Market Cap | 348.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -147.74M |
| EPS (ttm) | -3.08 |
| PE Ratio (ttm) | -1.79 |
| Forward PE | -2.14 |
| Analyst | Buy |
| Ask | 5.76 |
| Volume | 39,609 |
| Avg. Volume (20D) | 214,950 |
| Open | 5.64 |
| Previous Close | 5.86 |
| Day's Range | 5.49 - 5.70 |
| 52-Week Range | 4.77 - 16.63 |
| Beta | 1.56 |
About ABVX
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral re...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2023
Employees 69
Stock Exchange NASDAQ
Ticker Symbol ABVX
Website https://www.abivax.com
Analyst Forecast
According to 7 analyst ratings, the average rating for ABVX stock is "Buy." The 12-month stock price forecast is $42.5, which is an increase of 672.73% from the latest price.
Stock Forecasts
